In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations.IMpassion130: doi.org/10.1056/NEJMoa1809615Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters